Probabilities |
Prevalence of asthma | 323 500 | Fixed | [19] |
Percentage of mild asthma | 67.1% | Fixed | [4] |
Prevalence of genetic abnormality (GSTT1 null, GSTM1 null or GSTP1 Ile105) | 25% | Fixed | [20, 21] |
Risk of additional exacerbation in asthmatics with genetic abnormality, without preventive intervention | 55% | Beta (42.7, 34.9) | [22, 23] |
Risk of additional exacerbation in asthmatics with genetic abnormality, with preventive intervention | 5% | Beta (91.2,1732.5) | [22, 23] |
Risk of additional exacerbation in asthmatics without genetic abnormality (with or without preventive intervention) | 0 | Fixed | |
Unit costs |
Advair 500/50 twice per day (per month) | $74.7 | Fixed | [19] |
Exacerbation without hospitalisation | $126 | Gamma (96.04,0.76) | [24] (Converted to 2018 CAD) |
Exacerbation requiring emergency room visits | $575 | Gamma (96,0.17) | [24] (Converted to 2018 CAD) |
Exacerbation requiring hospitalisations | $6440 | Gamma (96,0.014) | [24] (Converted to 2018 CAD) |
Genetic testing | 109.43 | Fixed | [25] (Converted to 2018 CAD) |
Utilities |
Exacerbation without hospitalisation | 0.57 | Beta (0.51, 0.38) | [26] |
Exacerbation requiring emergency room visits | 0.45 | Beta (0.36, 0.45) | [26] |
Exacerbation requiring hospitalisations | 0.33 | Beta (0.15, 0.30) | [26] |